The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia

Schizophrenia Research

Volumn 90, Issue 1-3, 2007, Pages 229-237

  Remington, Gary ^a,b,c   Kwon, Jean ^b   Collins, April ^c   Laporte, Dan ^c   Mann, Steve ^b,c   Christensen, Bruce ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Compliance; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DEVICE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTPATIENT; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; CASE MANAGEMENT; DATA COLLECTION; DRUG PACKAGING; FEMALE; HUMANS; MALE; MICROCOMPUTERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT REFUSAL;

EID: 33846646917     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.11.015     Document Type: Article

References (49)

1. Awad A.G. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull. 19 (1993) 609-618
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
3. Bebbington P.E. The content and context of compliance. Int. Clin. Psychopharmacol. 9 Supplement 5 (1995) 41-50
4. Benton A.I., Sivan A.B., Des Hamsher K., Varney N.R., and Spreen O. Contributions to Neuropsychological Assessment (1994), Oxford University Press, New York
5. Bies R.R., Gastonguay M.R., Coley K.C., Kroboth P.D., and Pollock B.G. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am. J. Geriatr. Psychiatry 10 (2002) 696-705
6. Blackwell B. Compliance - measurement and intervention. Curr. Opin. Psychiatry 2 (1989) 787-789
7. Bova C.A., Fennie K.P., Knafl G.J., Dieckhaus K.D., Watrous E., and Williams A.B. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 9 (2005) 103-110
8. Buchanan R.W., and Carpenter Jr. W.T. Targeted maintenance treatment in schizophrenia: issues and recommendations. CNS Drugs 4 (1996) 240-245
9. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magourik B., and Rush A.J. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 133 (2005) 129-133
10. Carpenter Jr. W.T., Hanlon T.E., Heinrichs D.W., Summerfeldt A.T., Kirkpatrick B., Levine J., and Buchanan D.W. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am. J. Psychiatry 147 (1990) 1138-1148
11. Cramer J.A., and Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 49 (1998) 196-201
12. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., and Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. Jama 261 (1989) 3273-3277
13. David A.S. Insight and psychosis. Br. J. Psychiatry 156 (1990) 798-808
14. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J. Clin. Psychiatry 62 Supplement 22 (2001) 43-47
15. Diaz E., Levine H.B., Sullivan M.C., Sernyak M.J., Hawkins K.A., Cramer J.A., and Woods S.W. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J. Psychiatry Neurosci. 26 (2001) 325-329
16. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R., and Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 65 (2004) 354-360
17. Dolder C.R., Lacro J.P., Dunn L.B., and Jeste D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry 159 (2002) 103-108
18. Fenton W.S., Blyler C.R., and Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23 (1997) 637-651
19. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-CV) (1996), American Psychiatric Press Inc., Washington D.C.
20. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., and Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161 (2004) 692-699
21. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology, Publication ADM 76-338 (1976), National Institute of Mental Health, Rockville, MD
22. In: Haynes R.B., Taylor D.W., and Sackett D.L. (Eds). Compliance in Health Care (1979), The Johns Hopkins University Press, Baltimore
23. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., and Curtism G. Wisconsin Card Sorting Manual: Revised and Expanded (1993), Psychological Assessment Resources, Odessa, Fl
24. Horvath A. Working alliance inventory (WAI). In: Fischer J., and Corcoran K. (Eds). Measures for Clinical Practice. A Sourcebook (1987), The Free Press, New York 691-694
25. Hudson T.J., Owen R.R., Thrush C.R., Han X., Pyne J.M., Thapa P., and Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry 65 (2004) 211-216
26. Kampman O., and Lehtinen K. Compliance in psychoses. Acta Psychiatr. Scand. 100 (1999) 167-175
27. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
28. Knapp M., King D., Pugner K., and Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatry 184 (2004) 509-516
29. Kruse W., and Weber E. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur. J. Clin. Pharmacol. 38 (1990) 561-565
30. Leopold N.A., Polansky M., and Hurka M.R. Drug adherence in Parkinson's disease. Mov. Disord. 19 (2004) 513-517
31. Lezak M. Neuropsychological Assessment. third ed. (1995), Oxford University Press, New York
32. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. (1987) 1-100 (Supplement)
33. McKenney J.M., Munroe W.P., and Wrightm Jr. J.T. Impact of an electronic medication compliance aid on long-term blood pressure control. J. Clin. Pharmacol. 32 (1992) 277-283
34. Menzin J., Boulanger L., Friedman M., Mackell J., and Lloyd J.R. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr. Serv. 54 (2003) 719-723
35. Montanelli R.G., and Humphreys L.G. Latent roots of random data correlation matrices with squared multiple correlations on the diagonal: a Monte Carlo study. Psychometrika 41 (1976) 341-348
36. Nakonezny P.A., and Byerly M.J. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr. Res. 82 (2006) 107-114
37. Nose M., Barbui C., and Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol. Med. 33 (2003) 1149-1160
38. Procidano M.E., and Heller K. Perceived social support-family scale (PSS-Fa). In: Fischer J., and Corcoran K. (Eds). Measures for Clinical Practice. A Sourcebook vol 2 (1987), The Free Press, New York 421-425
39. Remington G., Seeman P., Shammi C., Mann S., and Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J. Clin. Psychopharmacol. 25 (2005) 611-613
40. Rittmannsberger H., Pachinger T., Keppelmuller P., and Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr. Serv. 55 (2004) 174-179
41. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., and Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999) 241-247
42. Shemesh E. Non-adherence to medications following pediatric liver transplantation. Pediatr. Transplant. 8 (2004) 600-605
43. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (1970) 11-19
44. Valenstein M., Barry K.L., Blow F.C., Copeland L., and Ullman E. Agreement between seriously mentally ill veterans and their clinicians about medication compliance. Psychiatr. Serv. 49 (1998) 1043-1048
45. Weiden P., Rapkin B., Zygmunt A., Mott T., Goldman D., and Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv. 46 (1995) 1049-1054
46. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr. Serv. 55 (2004) 886-891
47. Weiss K.A., Smith T.E., Hull J.W., Piper A.C., and Huppert J.D. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr. Bull. 28 (2002) 341-349
48. Young J.L., Zonana H.V., and Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull. Am. Acad. Psych. Law 14 (1986) 105-122
49. Zwick W.R., and Velicer W.F. Comparisons of five rules for determining the number of components to retain. Psychol. Bull. 99 (1986) 432-442